We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
PRODUCTS / PRODUCT PORTFOLIO
OTHER THERAPEUTIC AREAS

PRODUCT PORTFOLIO

Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, pain and respiratory diseases.
Product Indication Dosage form Strength
Depression Tablets 10 and 20 mg
Amitriptyline Major depressive disorders and anxiety Film-coated tablets 10, 25, 50 and 75 mg
Aripiprazole Schizophrenia, bipolar disorder Tablets 5, 10, 15, 20 and 30 mg
Baclofen Spasticity Injection 10 mg/5 ml and 10 mg/20 ml
Baclofen Spasticity Tablets 25 mg
Buprenorphine Opioid dependence 0,4/ 1/ 2/ 4/ 6 & 8 mg sublingual films
Clonazepam Epilepsy Oral drops, solution 2.5 mg/ml
Clonazepam Epilepsy Tablets 0.5 and 2 mg
Duloxetine * Major depressive disorders, neuropathic pain, anxiety Gastro resistant hard capsules 30, 60, 90 and 120 mg
Eslicarbazepine Epilepsy Tablets 400 and 1200 mg
Eslicarbazepine acetate Epilepsy Film-coated tablets 800 mg
Ethosuximide Epilepsy, absence seizures Soft capsules 250 mg
Ethosuximide Epilepsy, absence seizures Oral solution 250mg / 5ml
Fampridine Multiple sclerosis XR tablets 10 mg
Fingolimod Multiple sclerosis Capsules 0.5 mg
Flupentixol decanoate Schizophrenia Injection 10mg/ 0,5 ml;  20mg/ ml; 40mg/ ml; 200mg / 10 ml
Lacosamide Epilepsy Oral solution 10 mg/ml syrup
Lamotrigine Lamotrigine XR tablets 25/ 50/ 100/ 200 & 300 mg
Levetiracetam Epilepsy Film-coated tablets 250, 500, 750 and 1000 mg
Levetiracetam Epilepsy Granules for oral solution 250, 500, 750, 1000 and 1500 mg
FDF PRODUCT PORTFOLIO

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.


© Neuraxpharm / LESVI. All rights reserved.